Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 2/20 | 0.38 |
| ▸ | PDK1 | Q15118 | 3/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | EPHA2 | P29317 | 4/20 | 0.35 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.34 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.34 |
| ▸ | P2RX3 | P56373 | 3/20 | 0.33 |
| ▸ | P2RX2 | Q9UBL9 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18259388 | 0.89 | USP2 (0.39) | USP2SMN1; SMN2RECQLPDK1TSHR | |
| SCHEMBL18259389 | 0.89 | USP2 (0.39) | USP2SMN1; SMN2RECQLPDK1TSHR | |
| SCHEMBL18259390 | 0.89 | USP2 (0.39) | USP2SMN1; SMN2RECQLPDK1TSHR | |
| SCHEMBL22010255 | 0.89 | USP2 (0.39) | USP2SMN1; SMN2RECQLPDK1TSHR | |
| SCHEMBL23890968 | 0.82 | USP2 (0.46) | USP2SMN1; SMN2RECQLPDK1EPHA2 | |
| SCHEMBL18259315 | 0.81 | SMN1; SMN2 (0.43) | USP2SMN1; SMN2RECQLTSHRNR1H2 | |
| SCHEMBL18259317 | 0.81 | SMN1; SMN2 (0.43) | USP2SMN1; SMN2RECQLTSHRNR1H2 | |
| SCHEMBL23764590 | 0.81 | SMN1; SMN2 (0.43) | USP2SMN1; SMN2RECQLTSHRNR1H2 | |
| SCHEMBL18689037 | 0.81 | SMN1; SMN2 (0.43) | USP2SMN1; SMN2RECQLTSHRNR1H2 | |
| SCHEMBL18259316 | 0.81 | SMN1; SMN2 (0.43) | USP2SMN1; SMN2RECQLTSHRNR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239756-A1 | NOVEL 3, 5-DISUBSTITUTED PYRIDINE AND 3, 5-DISUBSTITUTED PYRIDAZINE DERIVATIVES AND PHARMACEUTICAL USE OF SAME | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2024-07-18 | — | — | US | disclosed |
| US-20240239756-A1 | NOVEL 3, 5-DISUBSTITUTED PYRIDINE AND 3, 5-DISUBSTITUTED PYRIDAZINE DERIVATIVES AND PHARMACEUTICAL USE OF SAME | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239756-A1 | NOVEL 3, 5-DISUBSTITUTED PYRIDINE AND 3, 5-DISUBSTITUTED PYRIDAZINE DERIVATIVES AND PHARMACEUTICAL USE OF SAME | ENPP2, SSB, PLPBP | USP2 1786/4885SMN1; SMN2 2393/4885RECQL 506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.